Pooling data on coastal zones.

and more. Immunol Today 1996; 17: 138–146. 9. Barnes PJ. Anti-IgE antibody therapy for asthma [editorial; comment]. N Engl J Med 1999; 341: 2006–2008. 10. de Vries JE, Carballido JM, Aversa G. Receptors and cytokines involved in allergic TH2 cell responses. J Allergy Clin Immunol 1999; 103: S492–S496. 11. Holt PG, Sly PD. Prevention of adult asthma by early intervention during childhood: potential value of new generation immunomodulatory drugs. Thorax 2000; 55: 700–703. 12. Strachan DP. Family size, infection and atopy: the first decade of the ‘hygiene hypothesis’. Thorax 2000; 55 (Suppl 1): S2–S10. 13. Holt PG, Stumbles PA. Regulation of immunologic homeostasis in peripheral tissues by dendritic cells: the respiratory tract as a paradigm. J Allergy Clin Immunol 2000; 105: 421–429. 14. Stumbles PA, Thomas JA, Pimm CL, Lee PT, Venaille TJ, Proksch S, Holt PG. Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity. J Exp.Med 1998; 188: 2019–2031. 15. Spiteri MA, Knight RA, Jeremy JY, Barnes PJ, Chung KF. Alveolar macrophage-induced suppression of peripheral blood mononuclear cell responsiveness is reversed by in vitro allergen exposure in bronchial asthma. Eur Resp J 1994; 7: 1431–1438. 16. Haczku A, Takeda K, Redai I, et al. Anti-CD86 (B7.2) treatment abolishes allergic airway hyperresponsiveness in mice. Am J Respir Crit Care Med 1999; 159: 1638–1643. 17. Van Oosterhout AJ, Hofstra CL, Shields R, Chan B, van Ark I, Jardieu PM, Nijkamp FP. Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in a murine model of allergic asthma. Am J Respir Cell Mol Biol 1997; 17: 386–392. 18. van Neerven RJ, Van de Pol MM, van der Zee JS, Stiekema FE, De Boer M, Kapsenberg ML. Requirement of CD28-CD86 costimulation for allergenspecific T cell proliferation and cytokine expression [see comments]. Clin Exp Allergy 1998; 28: 808–816. 19. Devalia JL, Davies RJ. Airway epithelial cells and mediators of inflammation. Resp Med 1993; 6: 405–408. 20. Saunders MA, Mitchell JA, Seldon PM, Barnes PJ, Giembycz MA, Belvisis MG. Release of granulocyte-macrophage colony-stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone. Br J Pharmacol 1997; 120: 545–546. 21. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999; 54: 825–857. 22. Corry DB, Kheradmand F. Induction and regulation of the IgE response. Nature 1999; 402: B18–B23. 23. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160: 1816–1823. 24. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258–2261. 25. Li L, Xia Y, Nguyen A, Lai YH, Feng L, Mosmann TR, Lo D. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol 1999; 162: 2477–2487. 26. Chomarat P, Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol 1998; 17: 1–52. 27. Humbert M, Durham SR, Kimmitt P, et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 1997; 99: 657–665. 28. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma [see comments]. Science 1998; 282: 2261–2263. 29. Leckie MJ, ten Brincke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 2000; 356: 2144–2148. 30. Levitt RC, McLane MP, MacDonald D, et al. IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. J Allergy Clin Immunol 1999; 103: S485–S491. 31. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, Presky DH. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998; 16: 495–521. 32. Gavett SH, O’Hearn DJ, Li X, Huang SK, Finkelman FD, Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsivness, inflammation and Th2 cytokine expression in mice. J Exp Med 1995; 182: 1527–1536. 33. Kim TS, DeKruyff RH, Rupper R, Maecker HT, Levy S, Umetsu DT. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol 1997; 158: 4137–4144. 34. Bryan S, O’Connor BJ, Matti S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyperreactivity and the late asthmatic response. Lancet 2000; 356: 2149–2153. 35. Kohno K, Kurimoto M. Interleukin 18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. Clin Immunol Immunopathol 1998; 86: 11–15. 36. Lack G, Bradley KL, Hamelmann E, et al. Nebulized IFN-gamma inhibits the development of secondary allergic responses in mice. J Immunol 1996; 157: 1432–1439. 37. Boguniewicz M, Martin RJ, Martin D, Gibson U, Celniker A. The effects of nebulized recombinant interferon-g in asthmatic airways. J Allergy Clin Immunol 1995; 95: 133–135. 38. Benjaponpitak S, Oro A, Maguire P, Marinkovich V, DeKruyff RH, Umetsu DT. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999; 103: 468–475. 39. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-g. J Allergy Clin Immunol 1996; 97: 1356–1365. 40. Pretolani M, Goldman M. IL-10: a potential therapy for allergic inflammation? Immunol Today 1997; 18: 277–280. 41. Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S. Interleukin10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 1996; 97: 1288–1296. 42. John M, Lim S, Seybold J, Robichaud A, O’Connor B, Barnes PJ, Chung KF. Inhaled corticosteroids increase IL-10 but reduce MIP-1a, GM-CSF and IFN-g release from alveolar macrophages in asthma. Am J Respir Crit Care Med 1998; 157: 256–262. 43. Zuany-Amorim C, Haile S, Leduc D, Dumarey C, Huerre M, Vargaftig BB, Pretolani M. Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. J Clin Invest 1995; 95: 2644–2651. 44. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102: 98–106. 45. Lim S, Crawley E, Woo P, Barnes PJ. Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet 1998; 352: 113. Mini Reviews